| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $148.9K | 0.00% | 157.50K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BFRI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 27, 2026 | Luebbert HermannChief Executive Officer | — | 62.5K | — |
| Jul 27, 2026 | Leffler Eugene FrederickChief Financial Officer | — | 31.3K | — |
| Mar 4, 2026 | Luebbert HermannChief Executive Officer | — | 137.5K | — |
| Mar 4, 2026 | Leffler Eugene FrederickChief Financial Officer | — | 87.5K | — |
| Sep 9, 2025 | Luebbert HermannChief Executive Officer | — | 137.5K | — |
| Sep 9, 2025 | Leffler Eugene FrederickChief Financial Officer | — | 87.5K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 63.2 | -1.9 | -11.3 | 33.5 | -18.0 | 6.8 | 23.7 | 30.8 | -29.4 | -17.4 | +56.5% | ||
| 2025 | 3.7 | -13.7 | -17.9 | -12.5 | -19.7 | 26.7 | 51.7 | -18.0 | 11.2 | 11.7 | -25.7 | -30.2 | −47.7% |
| 2024 | -52.0 | -37.0 | 83.8 | 19.5 | -44.0 | -12.8 | 33.6 | -9.2 | 22.0 | -7.5 | -26.8 | 21.1 | −60.6% |
| 2023 | -7.3 | -12.9 | -17.6 | -3.3 | -20.3 | 10.6 | 12.9 | -26.2 | 1.3 | -46.4 | -28.8 | -17.2 | −84.9% |
| 2022 | -54.9 | -13.0 | 12.9 | 11.1 | -22.4 | -35.2 | -23.1 | -18.9 | -9.5 | 2.9 | -2.8 | -12.7 | −87.8% |
| 2021 | 35.8 | 25.5 | +70.5% |
Buy / hold / sell counts
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.